The Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, the company has said, months after the pharmaceutical firm ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. The injectable drug will serve as an official partner of the Professional ...

Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in its deep portfolio achieving blockbuster sales. But the British ...

Camizestrant combination improves progression-free survival Trial to continue as planned after interim analysis Results "material positive surprise," say Barclays analysts Feb 26 (Reuters ...

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. The green light for ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

British-Swedish pharmaceutical giant AstraZeneca endured a torrid time in China last year, as it underwent several investigations and saw one of its senior executives detained by authorities.